Heath Canada – responsible for helping Canadians maintain and improve their health – has approved Berinert (C1 Esterase Inhibitor, Human) from CSL Behring for pediatric HAE.
“HAE is an unpredictable and life threatening disease with few treatment options approved for children,” said Paul Keith, M.D., Associate Professor, Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University. “Berinert’s new indication for use in the pediatric population provides a much needed treatment option for this vulnerable patient group.”
“The HAE Canada Team is so excited that CSL Behring listened to patients, caregivers, family members. This approval for Berinert in pediatric patients is a very important achievement for our children and parents living with HAE in Canada”, said Jacquie Badiou, President of HAE Canada.
Berinert is indicated for the treatment of acute abdominal, facial, or laryngeal attacks of HAE of moderate to severe intensity in pediatric and adult patients. The safety and efficacy of Berinert for prophylactic therapy has not been established.
(Source: CSL Behring)
